Literature DB >> 21741163

Prognostic factors and predictive models in renal cell carcinoma: a contemporary review.

Maxine Sun1, Shahrokh F Shariat, Christopher Cheng, Vincenzo Ficarra, Masaru Murai, Stéphane Oudard, Allan J Pantuck, Richard Zigeuner, Pierre I Karakiewicz.   

Abstract

CONTEXT: The natural history of renal cell carcinoma (RCC) is highly unpredictable. Small renal masses may be accompanied by metastatic disease. Conversely, patients with locally advanced disease may enjoy long-term disease-free survival.
OBJECTIVE: To review the status of prognostic factors in RCC. EVIDENCE ACQUISITION: A literature review was performed using the PubMed, MEDLINE, and Cochrane databases for articles published as of February 15, 2010. Electronic articles published ahead of print were also considered. Search was limited to the English language. Search was conducted using the following keywords: renal cell carcinoma, molecular, tissue, markers, blood, urine, progression, prognosis, risk factor, and survival. Studies were selected according to the relevance of the study, the number of patients included, originality, actuality, and clinical applicability of the results. EVIDENCE SYNTHESIS: Four areas of prediction were examined: (1) new RCC diagnostics, (2) RCC grade and stage at diagnosis, (3) disease progression, and (4) disease-specific mortality. All identified reports represented either case series or controlled studies. Although a large number of markers were identified, only a few were validated. Several prognostic factors were integrated in predictive or prognostic models.
CONCLUSIONS: Several prognostic factors can help discriminate between favourable and unfavourable RCC phenotypes. Of those, several clinical, pathologic, and biologic markers have been tested and validated, and they are used in predictive and prognostic models. Nonetheless, the search continues, especially for informative markers predicting the response to targeted therapies. Crown
Copyright © 2011. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741163     DOI: 10.1016/j.eururo.2011.06.041

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  125 in total

Review 1.  Role of cytoreductive nephrectomy in the era of targeted therapy for renal cell carcinoma.

Authors:  Paul L Crispen; Michael L Blute
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

2.  Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.

Authors:  Harun Fajkovic; Shahrokh F Shariat; Tobias Klatte; Mihai Dorin Vartolomei; Ilaria Lucca; Aurélie Mbeutcha; Morgan Rouprêt; Alberto Briganti; Pierre I Karakiewicz; Vitaly Margulis; Michael Rink; Mesut Remzi; Christian Seitz; Karim Bensalah; Romain Mathieu
Journal:  World J Urol       Date:  2016-02-15       Impact factor: 4.226

3.  Resampling phase III data to assess phase II trial designs and endpoints.

Authors:  Manish R Sharma; Theodore G Karrison; Yuyan Jin; Robert R Bies; Michael L Maitland; Walter M Stadler; Mark J Ratain
Journal:  Clin Cancer Res       Date:  2012-01-27       Impact factor: 12.531

4.  Kidney cancer: Characterizing late recurrence of renal cell carcinoma.

Authors:  Vincenzo Ficarra; Giacomo Novara
Journal:  Nat Rev Urol       Date:  2013-10-29       Impact factor: 14.432

Review 5.  Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma.

Authors:  Kyrollis Attalla; Stanley Weng; Martin H Voss; A Ari Hakimi
Journal:  Urol Clin North Am       Date:  2020-06-10       Impact factor: 2.241

6.  Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma.

Authors:  Malte Rieken; Stephen A Boorjian; Luis A Kluth; Umberto Capitanio; Alberto Briganti; R Houston Thompson; Bradley C Leibovich; Laura-Maria Krabbe; Vitaly Margulis; Jay D Raman; Mikhail Regelman; Pierre I Karakiewicz; Morgan Rouprêt; Mohammad Abufaraj; Beat Foerster; Mithat Gönen; Shahrokh F Shariat
Journal:  World J Urol       Date:  2018-11-07       Impact factor: 4.226

7.  [Clinical and pathological analysis of small renal cell carcinoma].

Authors:  X P Zhang; Z X Huang; L P Yu; X W Zhang; Q Li; S J Liu; T Xu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

8.  Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement.

Authors:  Umang Swami; Roberto H Nussenzveig; Benjamin Haaland; Neeraj Agarwal
Journal:  Ann Transl Med       Date:  2019-03

9.  Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma.

Authors:  Wassim Kassouf; Leonardo L Monteiro; Darrel E Drachenberg; Adrian S Fairey; Antonio Finelli; Anil Kapoor; Jean-Baptiste Lattouf; Michael J Leveridge; Nicholas E Power; Frederic Pouliot; Ricardo A Rendon; Robert Sabbagh; Alan I So; Simon Tanguay; Rodney H Breau
Journal:  Can Urol Assoc J       Date:  2018-05-31       Impact factor: 1.862

10.  Chest X-ray in the follow-up of renal cell carcinoma.

Authors:  B H J Doornweerd; I J de Jong; L M Bergman; H J K Ananias
Journal:  World J Urol       Date:  2013-10-06       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.